UPSIDE aims to research a minimally-invasive personalized therapy for Major Depressive Disorder by means of focused ultrasound. Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting 300 million people with a lifetime prevalence of 15%. Furthermore, approximately one third of all MDD patients fail to respond to currently established treatments based on medication and psychotherapy, thus falling into the category of Treatment-Resistant Depression (TRD) patients.



The UPSIDE project will result in a demonstrator which will allow, for the first time, network stimulation and simultaneous biomarker readout in behavioral experiments with animal models featuring depression-like symptoms. This technological breakthrough will pave the way towards a personalized treatment for TRD patients.



# **GET IN TOUCH**

### **Project Coordinator**



T.M.L.daCosta@tudelft.nl

#### Follow us on social media



upsideprojecteu

UpsideProjectEU

### Visit our website



www.project-upside.eu



Focused Ultrasound Personalized Therapy for the Treatment of Depression

UPSIDE

European Innovation Council



This project has received funding the Europe European Union's Horizon Europe EIC-PATHFINDER progamme under grant agreement No. 101070931

## WHY DO WE DO IT?

300 M people worldwide have MDD



Although, for 1/3 of the patients established treatments fail





technologies in place have poor precision, no monitoring or are highly invasive...



Transcranial MagneticElectroConvulsiveStimulationTherapy

**D**eep **B**rain **S**timulation

UPSIDE seeks to improve precision while being minimally invasive

TOWARDS A FULL PROOF-OF-CONCEPT EPIDURAL BRAIN INTERFACE (EBI)

# HOW DO WE DO IT?

Research and design energy-efficient CMOS circuits for interfacing with 2D arrays of ultrasound transducers and organic neural recording arrays.

Design and integrate ultrasound transducers and organic neural recording arrays with the CMOS interfaces in a biocompatible and flexible epidural system, to achieve a full EBI.

Research neural signal decoding tools to identify depression biomarkers to enable a personalized therapy for depression.

Assess safety and efficacy of the EBI in addressing depression-like symptoms in vivo, in behavioral rat models of depression.

